Finemark National Bank & Trust Reduces Stake in Eli Lilly

Hedge fund trims holdings in pharmaceutical giant by 8.3% in Q3

Mar. 3, 2026 at 12:23am

Got story updates? Submit your updates here. ›

Finemark National Bank & Trust, a hedge fund, reduced its position in Eli Lilly and Company by 8.3% in the third quarter, according to a filing with the Securities and Exchange Commission (SEC). The fund now owns 15,556 shares of the pharmaceutical company's stock, valued at $11.9 million as of the most recent SEC report.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, with a market cap of nearly $1 trillion. Changes in institutional ownership of its stock can signal shifts in investor sentiment and provide insights into the company's performance and outlook.

The details

Finemark National Bank & Trust sold 1,399 shares of Eli Lilly stock during the third quarter. The hedge fund now holds a total of 15,556 shares, down from 16,955 shares at the end of the previous quarter. Eli Lilly's stock price has risen significantly over the past year, up around 70% as the company has seen strong demand for its drugs.

  • Finemark National Bank & Trust filed its most recent 13F report with the SEC on March 1, 2026, disclosing its Q3 2025 holdings.
  • The 8.3% reduction in Eli Lilly shares occurred during the third quarter of 2025.

The players

Finemark National Bank & Trust

A hedge fund that manages investments for its clients.

Eli Lilly and Company

A global pharmaceutical company headquartered in Indianapolis, Indiana that develops and markets a wide range of medicines and therapies.

Got photos? Submit your photos here. ›

The takeaway

Finemark National Bank & Trust's reduction in its Eli Lilly holdings suggests the hedge fund may be taking a more cautious stance on the pharmaceutical company's stock, even as the broader market remains bullish on the company's performance and outlook.